Other cases of target-free combination therapy for pancreatic tumors have also been reported, such as a 55-year-old pancreatic cancer patient (cT4N1M1) with liver and lung metastases who carried ERBB2 mutation and had high tumor mutational load (TMB) being treated with lenvatinib in combination with pembrolizumab; it achieved partial remission for up to 5 months after a series of treatments failed (Chen et al., 2019). The gene discussed is ERBB2; the disease is pancreatic neoplasm.